Atenativ

DRUG3 trials

Sponsors

Octapharma AG, Vastra Gotaland Region, Octapharma

Conditions

Acquired Antithrombin Deficiency (Heparin Resistance)Antithrombin III DeficiencyCongenital Antithrombin Deficiency

Phase 3

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

RecruitingNCT04918173

OctapharmaCongenital Antithrombin Deficiency

Start: 2022-07-01End: 2026-06-01Target: 38Updated: 2025-11-21

Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (Atenativ) in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass

Active, not recruitingCTIS2023-507560-39-00

Octapharma AGAcquired Antithrombin Deficiency (Heparin Resistance)

Start: 2024-11-07Target: 34Updated: 2025-12-19

Phase 4

Atenativ Effect on Uterine Blood Flow and Preeclampsia

WithdrawnNCT02278575

Vastra Gotaland RegionAntithrombin III Deficiency

Start: 2016-01-31End: 2017-05-31Updated: 2017-09-26

Related Papers

Atenativ, a Plasma-Derived Antithrombin Concentrate, Used in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Parturition: Study Description (NCT04918173)

Blood2022-11-15

Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth

Blood2021-11-05